Manchester Medical Society

Events & Meetings

Become a member

Immunological aspects of disease

  • Date: Tuesday 28th April 2020 from 10.00 am-4.30 pm (Registration from 9.30 am)
  • Venue: Manchester Dental Education Centre (MANDEC), Higher Cambridge Street, Manchester, M15 6FH
  • Members from £25.00
  • Non Members £50-85

In light of the covid-19 coronavirus outbreak this meeting has now been cancelled. We hope to re-arrange it in the future.

Morning Session Chaired by Dr Shruthi Narayan

9.30 am

10.00 am                    
Welcome and Introduction

10.10 am                    
Spatial biomarkers for cancer prognosis: Applications in follicular lymphoma & head and neck cancer

Ms Anna Maria Tsakiroglou, Chemical Engineer (MEng) and CRUK PhD student in Digital Pathology, University of Manchester

Fulfilling the promise of cancer immunotherapy requires novel predictive biomarkers to characterise the host immune microenvironment. Automated multiplex approaches to histological analysis of tumour sections could assist with deciphering the complexity of immune cell interactions. Two studies demonstrating the prognostic utility of multiplexing and automated spatial analysis in histological sections will be presented; one in a cohort of oropharyngeal squamous cell carcinoma (N=72) and one in follicular lymphoma (N=130) from the Christie NHS Foundation Trust, Manchester.

10.40 am                    
Update on Amyloidosis

Dr Alberton Rocci, Consultant Haematologist, Manchester University NHS FT & Honorary Senior Lecturer

11.10 am                    
Coffee Break

11.30 am                     I
Speaker to be confirmed

12.30 pm                            
Monoclonal antibodies – the challenges for blood transfusion
Dr Josephine McCullagh, Clinical Scientist and Blood Transfusion Clinical Lead, Bolton NHS Foundation Trust and honorary contract with NHS Blood and Transplant (NHSBT)

Learning Objectives:

  • Understand the effect of monoclonal antibodies on transfusion testing.
  • Recognise the importance of communication.
  • Be aware of the processes that can reduce the challenges that these monoclonal treatments pose.

1.00 pm                               

Afternoon Session Chaired by Dr Richard Byers

1.30 pm                      
Using immune cells as drugs

Professor Fiona Thistlethwaite, Medical Oncology Consultant ECMT; Honorary Professor, University of Manchester; iMATCH Director, The Christie NHS FT


The immune system has long been recognised as playing a vital role in the development of cancer. In recent years oncology treatment has been transformed with the introduction of immunotherapies, primarily a group of drugs called checkpoint inhibitors. These antibody treatments can result in activation of a cell mediated tumour response and can result in dramatic clinical responses. However, to date these drugs are only effective for a significant number of patients in a minority of cancers and can have significant toxicities. Investigators have therefore looked towards other immunotherapeutic approaches. These include the adoptive transfer of activated and/or gene modified cells known as ‘Advanced Therapies’. There has been particular interest in the use of T cells, with one example being CAR-T (chimeric antigen receptor-T) cells targeting the B cell antigen CD19. Remarkable and durable responses have been seen in the haematological setting with this approach and CD19 CAR-T cells are now a standard-of-care treatment being delivered within the NHS. However, in the solid tumour setting CAR-T therapy has met with limited success, although using T cells isolated directly from tumour, TIL (tumour infiltrating lymphocytes), can produce durable remissions in the setting of melanoma. New innovations and approaches are being explored including TCR-gene modified T cells, neo-antigen directed TIL and allogeneic ‘off the shelf’ products. These emerging developments will be discussed alongside the challenges of delivering these complex therapies within the setting of the NHS.

Learning objectives:

  • The immune system is increasingly being harnessed to induce anti-cancer responses in oncology
  • Adoptive cell therapy (ACT) approaches can show remarkable and durable benefit for patients and CAR-T therapies are now part of standard-of-care for some haematological malignancies
  • The field of Advanced Therapies is developing rapidly with many new products currently in development across a range of malignancies

2.30 pm                      
Endocrine aspects of newer immunological therapies

Dr Claire Higham, Consultant Endocrinologist, The Christie NHS FT

3.00 pm
Coffee break

3.20 pm                      
Drug allergy – what actually is it?

Dr Tomaz Garcez, Consultant Immunologist, Manchester University NHS FT

3.50 pm                      

Dr Anshuman Chaturvedi, Consultant Histopathologist, The Christie NHS FT

4.20 pm
Feedback and Wrap-up

4.30 pm